GlassScriptPhysician profile
Leigh Beth Brown
NPI 1689281685
$8,660.93
in general payments reported to CMS, 2019-2025
35 companies · $2,606 in 2025
The $2,606 reported for 2025 was more than what 97% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,003 · 2022: $1,295 · 2023: $1,737 · 2024: $2,020 · 2025: $2,606.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,254 · Education: $109.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,254.34 |
| Education | $108.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,139.41 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $942.88 | 2021-2025 | Xifaxan, Trulance, Plenvu |
| Takeda Pharmaceuticals U.S.A., INC. | $892.16 | 2021-2025 | Entyvio, Gattex, Eohilia |
| Genzyme Corporation | $737.05 | 2022-2025 | |
| Janssen Biotech, INC. | $660.81 | 2021-2025 | Tremfya, Stelara, Simponi Aria |
| Intercept Pharmaceuticals, INC. | $416.39 | 2021-2025 | Ocaliva |
| Lilly USA, LLC | $407.98 | 2023-2025 | Omvoh, Zepbound |
| Madrigal Pharmaceuticals | $327.23 | 2024-2025 | Rezdiffra, Resmetirom |
| Regeneron Healthcare Solutions, INC. | $301.94 | 2023-2025 | Dupixent |
| Gilead Sciences, INC. | $299.05 | 2023-2025 | |
| Pfizer INC. | $287.91 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $272.89 | 2021-2024 | Dificid |
| Qol Medical, LLC | $242.45 | 2021-2025 | Sucraid, Sucraid |
| Aimmune Therapeutics, INC. | $231.81 | 2024-2025 | Zenpep |
| Daiichi Sankyo INC. | $229.81 | 2021-2025 | Injectafer |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironwood Pharmaceuticals, INC | $156.85 | 2022-2024 | Linzess |
| Phathom Pharmaceuticals, INC. | $149.45 | 2024-2025 | Voquezna |
| Enterra Medical, INC. | $144.73 | 2023-2025 | |
| Redhill Biopharma INC. | $141.77 | 2021 | |
| Celgene Corporation | $123.99 | 2021-2024 | Zeposia |
| Ardelyx, INC. | $120.11 | 2022-2025 | Ibsrela |
| Celltrion USA INC. | $98.70 | 2024-2025 | Vegzelma, Zymfentra |
| Nestle Healthcare Nutrition INC. | $71.38 | 2021-2022 | |
| Ipsen Biopharmaceuticals, INC | $53.83 | 2025 | Iqirvo |
| Micro-Tech Endoscopy USA, INC. | $30.04 | 2024 | Lesionhunter, Riteclip |
| Sandoz INC. | $24.15 | 2025 | Hyrimoz |
| Evoke Pharma, INC. | $21.99 | 2025 | |
| Intra-Sana Laboratories | $20.42 | 2022 | |
| Medtronic, INC. | $19.99 | 2025 | Interstim |
| Fresenius Kabi USA, LLC | $19.29 | 2023 | Idacio |
| Amgen INC. | $17.82 | 2021 | |
| Ferring Pharmaceuticals INC. | $16.72 | 2023 | Rebyota |
| Novo Nordisk INC | $14.94 | 2025 | Wegovy, Saxenda |
| Boston Scientific Corporation | $13.40 | 2022 | |
| Braintree Laboratories, INC. | $11.59 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leigh Beth Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.